Vegas stocks,
Many, many reporters are aware of leronlimab.
However, despite all the great anecdotal information, there is not YET rigorous proof.
Despite my previous long post, nothing is known yet by us. The CD12 trial could fail.
Reporters aren’t lining up to stick their necks out for this tiny company.
We here (mostly) have investigated to the limits of our resources and bet considerable collective wealth on our beliefs that leronlimab is the real deal.
Either we are proved correct and we can say “‘I told you so” on our way to cash in our winnings or the reporters will pat themselves on the back for maintaining their careers by not risking their reputations on these “fantastic” claims.
Again, a bit of a binary event with little chance of anyone acting until results are known.
Market Data 
Markets 
AI
